PDCD1 and neoplasm: Therefore, GITR agonist and PD-1 blockade modestly increased the percentage of CD8+ T cells in the tumor and the addition of peritumoral DR-BMCs skewed the tumor CD4+ T-cell compartment towards an immune-stimulating response.